Tags

Type your tag names separated by a space and hit enter

Abrocitinib: a potential treatment for moderate-to-severe atopic dermatitis.
Expert Opin Investig Drugs. 2020 Sep; 29(9):911-917.EO

Abstract

INTRODUCTION

Atopic dermatitis (AD) is a common and debilitating dermatosis that often impacts the physical and psychological quality of life in children and adults. A limited number of treatment options are available for AD, and often these treatments result in an insufficient response or may be contraindicated for some patients. This treatment gap creates an increasing demand for alternative AD therapies. The Janus kinase (JAK)-signal transducers and activators of transcription (STAT) pathway is known to play a critical role in the dysregulation of immune responses in AD. Inhibition of the JAK enzymes in the JAK-STAT pathway has shown potential for the treatment of this chronic skin condition.

AREAS COVERED

We review the evolving efficacy and safety profile of abrocitinib, an oral JAK1 inhibitor, in the treatment of AD based on the data available from phase I, II, and III clinical trials.

EXPERT OPINION

Evidence supports clinical efficacy, improved pruritus and an acceptable safety profile, making abrocitinib a viable alternative to conventional AD therapies. Pivotal phase III trials included subjects aged 12 years and above, providing a new mechanism of action for future treatment of adolescent and adult AD. Further investigations are required to have a thorough understanding of abrocitinib in the treatment of AD.

Authors+Show Affiliations

Skin Centre for Dermatology , Peterborough, ON.Space Studies, International Space University , Illkirch-Graffenstaden, France.Skin Centre for Dermatology , Peterborough, ON. Department of Medicine, Queen's University , Kingston, ON. Probity Medical Research , Waterloo, ON.Probity Medical Research , Waterloo, ON. K Papp Clinical Research , Waterloo, ON.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32741227

Citation

Nezamololama, Novin, et al. "Abrocitinib: a Potential Treatment for Moderate-to-severe Atopic Dermatitis." Expert Opinion On Investigational Drugs, vol. 29, no. 9, 2020, pp. 911-917.
Nezamololama N, Crowley EL, Gooderham MJ, et al. Abrocitinib: a potential treatment for moderate-to-severe atopic dermatitis. Expert Opin Investig Drugs. 2020;29(9):911-917.
Nezamololama, N., Crowley, E. L., Gooderham, M. J., & Papp, K. (2020). Abrocitinib: a potential treatment for moderate-to-severe atopic dermatitis. Expert Opinion On Investigational Drugs, 29(9), 911-917. https://doi.org/10.1080/13543784.2020.1804854
Nezamololama N, et al. Abrocitinib: a Potential Treatment for Moderate-to-severe Atopic Dermatitis. Expert Opin Investig Drugs. 2020;29(9):911-917. PubMed PMID: 32741227.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Abrocitinib: a potential treatment for moderate-to-severe atopic dermatitis. AU - Nezamololama,Novin, AU - Crowley,Erika L, AU - Gooderham,Melinda J, AU - Papp,Kim, Y1 - 2020/09/30/ PY - 2020/8/4/pubmed PY - 2021/2/3/medline PY - 2020/8/4/entrez KW - Abrocitinib KW - JAK-STAT Pathway KW - JAK1 KW - PF-04965842 KW - atopic dermatitis KW - eczema SP - 911 EP - 917 JF - Expert opinion on investigational drugs JO - Expert Opin Investig Drugs VL - 29 IS - 9 N2 - INTRODUCTION: Atopic dermatitis (AD) is a common and debilitating dermatosis that often impacts the physical and psychological quality of life in children and adults. A limited number of treatment options are available for AD, and often these treatments result in an insufficient response or may be contraindicated for some patients. This treatment gap creates an increasing demand for alternative AD therapies. The Janus kinase (JAK)-signal transducers and activators of transcription (STAT) pathway is known to play a critical role in the dysregulation of immune responses in AD. Inhibition of the JAK enzymes in the JAK-STAT pathway has shown potential for the treatment of this chronic skin condition. AREAS COVERED: We review the evolving efficacy and safety profile of abrocitinib, an oral JAK1 inhibitor, in the treatment of AD based on the data available from phase I, II, and III clinical trials. EXPERT OPINION: Evidence supports clinical efficacy, improved pruritus and an acceptable safety profile, making abrocitinib a viable alternative to conventional AD therapies. Pivotal phase III trials included subjects aged 12 years and above, providing a new mechanism of action for future treatment of adolescent and adult AD. Further investigations are required to have a thorough understanding of abrocitinib in the treatment of AD. SN - 1744-7658 UR - https://www.unboundmedicine.com/medline/citation/32741227/Abrocitinib:_a_potential_treatment_for_moderate_to_severe_atopic_dermatitis_ L2 - https://www.tandfonline.com/doi/full/10.1080/13543784.2020.1804854 DB - PRIME DP - Unbound Medicine ER -